First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors

Kadcyla (ado-trastuzumab emtansine) - Roche

Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca

ADC2122 - ZovaBio, Adcoris

Perjeta (pertuzumab) - Roche

F. Lin1; Y. Huang2; Y. Huang2; Y. Lu2; X. Rao3; X. Wang2; F. Wang2; X. Huang2

Jul 19, 2024